SG Americas Securities LLC Has $1.15 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

SG Americas Securities LLC boosted its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 117.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,244 shares of the biotechnology company's stock after acquiring an additional 1,751 shares during the period. SG Americas Securities LLC's holdings in United Therapeutics were worth $1,145,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of UTHR. MBM Wealth Consultants LLC raised its position in shares of United Therapeutics by 1.9% during the fourth quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company's stock valued at $775,000 after buying an additional 41 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in United Therapeutics by 11.9% during the fourth quarter. Nisa Investment Advisors LLC now owns 25,499 shares of the biotechnology company's stock worth $8,997,000 after buying an additional 2,720 shares in the last quarter. Perpetual Ltd boosted its stake in United Therapeutics by 62.0% during the fourth quarter. Perpetual Ltd now owns 1,170 shares of the biotechnology company's stock worth $413,000 after buying an additional 448 shares in the last quarter. Atwood & Palmer Inc. increased its holdings in United Therapeutics by 0.8% in the 4th quarter. Atwood & Palmer Inc. now owns 64,575 shares of the biotechnology company's stock valued at $22,785,000 after buying an additional 519 shares during the period. Finally, MassMutual Private Wealth & Trust FSB raised its stake in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after buying an additional 58 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Trading Down 0.2 %

Shares of UTHR stock traded down $0.84 on Friday, reaching $351.46. The company had a trading volume of 258,120 shares, compared to its average volume of 287,817. The company has a 50-day moving average of $365.47 and a 200-day moving average of $356.78. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The stock has a market cap of $15.69 billion, a PE ratio of 15.44, a PEG ratio of 0.95 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to analysts' expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business's quarterly revenue was up 22.9% compared to the same quarter last year. During the same period last year, the firm posted $5.38 earnings per share. Sell-side analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,485,785.60. This represents a 17.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $370.71, for a total value of $3,707,100.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $955,319.67. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 133,838 shares of company stock valued at $50,445,556 over the last 90 days. 11.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of analyst reports. LADENBURG THALM/SH SH upped their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. UBS Group boosted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Argus increased their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. The Goldman Sachs Group lifted their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a research report on Friday, November 1st. Finally, StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, January 16th. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $378.36.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.